Summary.-Mononuclear cell fractions were isolated from blood, ascites and solid tumours of patients undergoing surgery for Stages III and IV PHA responses of patient blood and ascites fractions were about half that of normal blood. Tumour-infiltrating lymphocytes (TIL) were less than 10% as responsive as normal blood. The depressed PHA responses of the TIL were not due to the presence of a suppressor cell population. NK activity of patient blood was less than that of normal blood, but not as much as the ascites or TIL cells. The activity of the ascites-derived lymphocytes was enhanced by treatment with interferon. ADCC activity against both CRBC and SB cells was normal or higher than controls in patient blood, and depressed in the ascites-derived fractions. TIL responded to <10% of the patient blood values.
SUCCESSFUL monitoring of antitumour immunity depends on a knowledge of both systemic and intratumour immunological events. Because blood represents essentially the sole source by which immune competence can be followed, it is important to determine whether activity in patient peripheral-blood leucocytes is representative of what is actually taking place in the tumour. There have been numerous reported investigations of the tumour-and ascites-isolated macrophages and lymphocytes from both animals (Russell et al., 1980; Herbermann et al., 1980; Haskill et al., 1979 Haskill et al., , 1978 and humans (Mantovani et al., 1979; Klein et al., 1980; Werkmeister et al., 1979; Vose & Moore, 1979; Totterman et al., 1980) with various results in animals, but most of the clinical studies have failed to detect intratumour activity. In addition, many of these studies have not focused on a particular cancer type, making the results more difficult to compare.
We have initiated a study of the immune competence of the inflammatory cell types infiltrating solid and ascitic ovarian tumours derived from patients prior to therapy. In the accompanying paper (Haskill et al., 1982) we outline the methods of isolating these cells, and their cell markers. Two classes were characterized: those sedimenting less than 6mm/h and similar in size to most of the blood cells and a series of larger macrophages cytochemically distinct from blood monocytes, which sediment with tumour cells.
The present report documents the activity of the blood-like cells, in both patient and normal blood mononuclear cell fractions. The data indicate a general lack of functional NK, ADCC and PHA response, with the exception of ascitic inflammatory cells, where mitogenic activity resembles that in autologous blood.
MATERIALS AND METHODS
Human subjects-Thirty-eight patients with histologically confirmed epithelial cancer of the ovary were used in this study. All but one were classified as Stages III or IV. Most patients provided both ascites and solid-tumour material for analysis. In several cases, both ovarian and omental tumour sites were obtained. Because surgical removal of the ovary left only the extensive omental tumour to be treated, when available, this tissue was used for analysis, as it represented the target for further therapy.
Heparinized venous blood was collected from patients at surgery, when available. Healthy laboratory workers supplied control blood.
Enzymatic digestion of the tumours and sedimentation-velocity separation.-The general methodologies have been extensively described in Haskill et al., 1982. Mitogen response. /Ci/501A was added to the target cells, which were then incubated in a 37 0C water bath for 1 h with occasional shaking. Labelled target cells were washed x 3 with MEM-10% and adjusted to the desired concentration.
Assay for NK activity.-Effector cells were tested against 51Cr-labelled K562 targets. Triplicate determinations were made in U-bottomed microtitre plates (Linbro, Is-MRC-96TC) in a total volume of 0-2 ml. Effector cells were tested in every experiment at 3 concentrations, against a constant dose of target cells, producing 20: 1, 10:1 and 5: 1 E: T ratios. Results presented in this paper include only one E: T ratio. The tumour targets were added at 104 cells/well. The plates were centrifuged for 3 min at 80 g to facilitate cell contact, and then incubated for an additional 2 h at 37°C in a humidified 7% CO2 incubator. The assay was terminated by centrifuging the plates for 5 min at 500 g, and subsequently harvesting 0-1 ml of the supernatant.
Assay for ADCC activity.-Both SB and CRC targets were modified with trinitrobenzene sulphonic acid, as previously described (Snyderman et al., 1977) . The haptenated cells will be referred to as SB-TNP fNFLAMMATORY CELLS IN OVARIAN CANCER. II and CRC-TNP. A portion of the modified cells (51Cr-labelled SB-TNP and cold SB-TNP and CRC-TNP) were then adjusted to 106 cells/ml and incubated with rabbit hyperimmune anti-TNP serum for 30 min at 37°C. SB-TNP targets were coated with a 1:480 final dilution of anti-TNP serum in MEM-10%, whereas the CRC-TNP targets were coated in a 1:2400 dilution to avoid agglutination of these targets. Anti-TNPcoated target cells, designated SB-TNP-anti-TNP and CRC-TNP-anti-TNP, were then washed x 3 to remove excess anti-TNP serum from the medium, and adjusted to the desired concentration. As in the case of NK assays, effector cells were tested at 3 concentrations against a 104 51Cr-labelled SB-TNP-anti-TNP, but results from only one E : T ratio are presented. The subsequent steps of the assay were identical to those of the NK assays.
Calculation of cytoxicity.-For both the NK and ADCC assays, spontaneous release (SR) was defined as ct/min released from targets incubated with medium alone. Maximal release (MR) was determined by measuring ct/min in the supernatants after detergent lysis (1% Triton x 100) of the various target cells. The formula used to calculate the percent specific release was: ct/min (experimental) -ct/min (spontaneous) ct/min (maximal) -ct/min (spontaneous) Data were calculated and statistically analysed by a program using the above formula, with a PDP 11/20 computer (Digital Equipment Corp., Maynard, Mass.).
Treatment with interferon (IFN).-Cells (2 x 106/ml) were incubated with 100 u/ml of IFN (partially purified human IFN, Hem Research kindly provided by Dr J. Ortaldo) for 18 h in 12-75 mm tubes at 37°C. The cells were then washed twice with MEM-10% and then assayed for cytotoxicity.
RESULTS

Mitogen response
The methods used are summarized in Fig. 4 .
Although 3 different concentrations of lymphocytes were used in each experiment, to simplify the presentation, only the results obtained at 104 cells/well are given. Because similar dose-response rela- Tumour (TuL) and ascites (AscL) mononuclear cell fractions were obtained by sedimentation-velocity separation (Haskill et al., 1982) . The mean E RFC values for each cell source are given in Fig. 4 Natural killer cell (NK) activity NK activity was assessed with the K562 cell as target, using the same effector cell populations as described above for PHA responses. The results of these assays indicated a considerable spread in activity between both normal and patient blood values. However, it was clear that both ascites and TIL cells responded poorly, with little overlap between blood and tumour values (Fig. 3) . Although the overall response of these Fractions and Symbols are as in Fig. 1 . NK activity against the K562 target cell, and ADCC activity against the tumourcell target (SB) or erythrocyte target (CRC) were determined at 3 ratios, but only the data for one of these is given (E: T = 20: 1 for NK and ADCC (SB) and 3: 1 for ADCC (CRC)). The bars represent the means.
cells was low, 6/12 ascites values were >50% of the autologous blood values (Table I) , suggesting that at least part of the lack of response of ascites-derived lymphocytes may have been a more general phenomenon than a function of the ascites environment. Only 2/11 TIL samples responded >50% of autologous blood (Table I) .
ADCC activity
Two different target cells were used to assess the ADCC competence of blood, ascites and TIL cells. The CRC assay detects both macrophage and K-cell killing (Lovchik & Hong, 1977) whilst the SB tumour targets are killed primarily by K cells (Lovehik & Hong, 1977) and activated macrophages (Koren et al., 1981) . Activity against both the CRC and SB target cells was at least as high in patient blood as normal blood. Both the ascites and tumour-associated sites provided effector cells of low specific activity against both the SB and CRC targets. Only on 1/9 occasions did the response of the TILs exceed 50% of autologous blood (SB target) ( Table I ).
Effect of collagenase treatment on cell markers and function
Collagenase is a relatively gentle proteolytic enzyme, and thus often used for tumour disaggregation. It has been shown that membrane glycoproteins, T-and B-cell markers and Fc receptors are not affected by short-term treatment with collagenase (Hayry & Totterman, 1978) . We also studied the potential that collagenase might have for influencing the various cellular effector activities studied herein. Collagenase treatment of normal blood lymphocytes for 20 min under the same conditions as in tumour disaggregation did not affect activity (Table II) , nor did it change sedimentationvelocity distribution patterns (data not shown).
Association of cell markers with effector-cell activity
As lack of effector-cell activity could arise from an absence of the lymphocyte subset from the tumour site, it was of (Moretta et al., 1978) . NK cells are known to belong to another T-cell subset which is characterized by a lack of ANAE staining and a (Fig. 4) .
distinct granular staining with Giemsa. They are referred to as large granular lymphocytes (LGL) (Saksela et al., 1979a) . Fc R+ ADCC activity against the SB target cell is associated with FcR-bearing E RFC cells, including cells of the NK class of lymphocytes (Kall & Koren, 1978 (LGL) were present in the patient blood (Table III) they were not active. Because of the low activity in blood in the presence of the marker, the absence of both activity and the LGL marker from the ascites fraction need not be related. Although several experiments were conducted to investigate the presence of suppressor cells of the NK activity, we were unable to detect them.
ADCC: SB target-cell assay.-Although there is generally a close association in properties between NK cells and ADCC effector cells to this target, it seems probable that the high activity in patient blood in contrast to NK activity, represents another example of the dissociation of these two activities .
ADC: CaRBO target-cell assay.-As monocytes are known to participate in the lysis of this target cell (Lovehik & Hong, 1977 ) it was anticipated that the level of NSE+ cells of monocytic morphology would give a representation of this effector cell. The data indicate, however, that there is little relationship between mean ADCC values and average levels of monocytes in the TIL fraction. This would appear to indicate that cells morphologically characteristic of effector cells in this assay are present but inactive.
Effect of ascites fluid on blood-lymphocyte reactivity Effector-cell activity (NK, ADCC) associated with FcR+ cells from ovarian ascites is generally very depressed. However, ascites fluids are known to contain immunosuppressive factors (Hess et al., 1979) as well as immune complexes (Poulton et al., 1978) . Several attempts were made to influence activity in each assay by incubating normal blood mononuclear cells overnight with 18 different ascitic fluids, associated with either the most depressed or most active of values for ascitic NK activities. None of the fluids influenced PHA activity, whilst 3/18 depressed NK activity by < 30% (data not shown).
Effect of interferon on blood and ascites lymphocyte reaction to K562C
Several reports have indicated that interferon (IFN) can enhance NK activity, either through stimulation of pre-NK cells (Saksela et al., 1979b) or stimulation of endogenous NK activity (Zarling et al., 1980) . A similar study to the present one (Mantovani et al., 1980) indicates that depressed levels of ascites NK activity can be stimulated by IFN. Our results confirm this observation and suggest that enhancement of cytotoxicity occurs after overnight incubation of ascites lymphocytes with IFN (Table IV) . Although the mean augmentation of activity was (Underwood, 1974; Ioachim, 1976) . In an attempt to delineate the role played by various effector mechanisms in situ, numerous studies have been reported in which tumour infiltrating cells have been isolated from highly immunogenic animals tumours (Russell et al., 1980; Herberman et al., 1980; Haskill et al., 1979 Haskill et al., , 1978 as well as from human tumours (Mantovani et al., 1979; Klein et al., 1980; Werkmeister et al., 1979; Totterman et al., 1980; Vose & Moore, 1979) . Several studies have investigated the in vitro activity of TILs from human tumours but none have attempted to find an association between effector-cell presence and survival. Although it is the hope of tumour immunologists that recognition and infiltration of cancer is immune in nature, infiltration of an inflammatory site may be nonspecific (Koster et al., 1971) . Therefore, a tumour undergoing necrotic changes, blood vessel development and destruction could well contain cells attracted through a variety of non-specific mechanisms.
Systemic and in situ immunity need not be directly comparable (Haskill et al., 1978) . While very little is known about restrictions on lymphocyte localization in tumours, several studies suggest that the distribution of these cells varies with the anatomic and perhaps the inflammatory site. Lymphocytes infiltrating sites of inflammation are likely to be long-lived (Mule et al., 1979) , The proportions of ANAE+ T cells are markedly different in blood and lymph nodes (Moretta et al., 1978) . Lymphocytes isolated from normal lung washings of both humans (Daniele et al., 1975) and dogs (Ansfield et al., 1979) (Saksela et al., 1979a) . Vose et al. in 1977 (reviewed in Klein et al., 1980 carried out a more extensive and detailed investigation of TIL function in a wide spectrum of cancer types, including nasopharyngeal carcinoma, var-ious primary and secondary lung tumours and sarcomas. Their data indicate a number of valuable points. First, tumour type may play an important role in the results obtained. Lymphocytes from only 2/12 lung tumours were cytolytic against autologous target cells, whereas 9/18 other carcinomas and sarcomas had demonstrable activity. NK activity was absent from all but 1/41 preparations of TIL. Mantovani et al. (1980) have recently reported an extensive series of experiments using ovarian ascites lymphoid cells in the NK assay. They observed activity in blood and ascites, though blood was usually the higher and both were significantly below control blood values. The two normal PC populations showed very little activity. Our results indicated a similar depression of patient blood activity, but a greater drop in NK activity, when ascites lymphoid cells were used. There are several possibilities for this discrepancy. Mantovani et al. (1980) used a 20h assay, whereas we used a 4h assay; however, they have data suggesting that this may be unimportant. Our ascites lymphocyte fraction averaged 77% E RFC whereas those used by Mantovani et al. (1980) averaged 39% E RFC. Levels of FcR+ cells were similar. As the values for blood E RFC are within the expected values, the twofold differences in T-cell levels must be related either to the separation procedures or to the patient population.
Our separation method used only one step in isolating a mononuclear-cell fraction from tumour or ascites preparations. In the studies of Mantovani et al. (1980) several approaches were used, both of which involved, step-wise, enrichment procedures which may have produced depletion of particular segments of the various lymphocyte and monocyte populations.
In summary, these data indicate that TILs in ovarian cancer are in general low in activity in our 4 tests, whereas ascites preparations were more variable in degree of response. It is concluded that several factors, including immunosuppression due to cancer, and selective immigration, may account for the low activity associated with many patients.
